Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Lanfear

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
Cardiology in Review|August 6, 2014
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?Akinyemi Oni-Orisan, David E Lanfear
JACC. Basic to Translational Science|July 5, 2021
BNP and Precision Medicine: Tip of an IcebergDavid E Lanfear, Jasmine A Luzum
Journal of Cardiovascular Pharmacology and Therapeutics|June 10, 2015
Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical PractitionerAnna T Sleder, James Kalus, David E Lanfear
Pharmacogenomics|December 15, 2025
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversionBayan Azizi, David E Lanfear, Jasmine A Luzum
Clinical Pharmacology and Therapeutics|August 4, 2004
Caution with beta1-adrenergic receptor genotypingDavid E Lanfear, Sharon Marsh, Howard L McLeod
Journal of Cardiac Failure|April 3, 2008
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trialsRachid Lakhdar, Mouaz H Al-Mallah, David E Lanfear
The International Journal of Artificial Organs|March 31, 2012
Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devicesDouglas L Jennings, Mathew C Jones, David E Lanfear
The Journal of Cardiovascular Nursing|February 13, 2007
Beta2-adrenergic receptor genotype predicts survival: implications and future directionsDavid E Lanfear, John A Spertus, Howard L McLeod
The Annals of Pharmacotherapy|March 21, 2009
Effect of "energy drink" consumption on hemodynamic and electrocardiographic parameters in healthy young adultsLeah Steinke, David E Lanfear, Vishnuprabha Dhanapal, et al.
Heart Failure Reviews|May 1, 2015
Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipientsDouglas L Jennings, Brandon Martinez, Sheila Montalvo, et al.
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
Cardiology in Review|August 6, 2014
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?Akinyemi Oni-Orisan, David E Lanfear
JACC. Basic to Translational Science|July 5, 2021
BNP and Precision Medicine: Tip of an IcebergDavid E Lanfear, Jasmine A Luzum
Journal of Cardiovascular Pharmacology and Therapeutics|June 10, 2015
Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical PractitionerAnna T Sleder, James Kalus, David E Lanfear
Pharmacogenomics|December 15, 2025
Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversionBayan Azizi, David E Lanfear, Jasmine A Luzum
Clinical Pharmacology and Therapeutics|August 4, 2004
Caution with beta1-adrenergic receptor genotypingDavid E Lanfear, Sharon Marsh, Howard L McLeod
Journal of Cardiac Failure|April 3, 2008
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trialsRachid Lakhdar, Mouaz H Al-Mallah, David E Lanfear
The International Journal of Artificial Organs|March 31, 2012
Assessment of the heart failure pharmacotherapy of patients with continuous flow left-ventricular assist devicesDouglas L Jennings, Mathew C Jones, David E Lanfear
The Journal of Cardiovascular Nursing|February 13, 2007
Beta2-adrenergic receptor genotype predicts survival: implications and future directionsDavid E Lanfear, John A Spertus, Howard L McLeod
The Annals of Pharmacotherapy|March 21, 2009
Effect of "energy drink" consumption on hemodynamic and electrocardiographic parameters in healthy young adultsLeah Steinke, David E Lanfear, Vishnuprabha Dhanapal, et al.
Heart Failure Reviews|May 1, 2015
Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipientsDouglas L Jennings, Brandon Martinez, Sheila Montalvo, et al.
Pageof 18